Viralytics is developing targeted Oncolytic Virotherapeutics to treat cancer using its proprietary Oncolytic Virotherapy technology.

Viralytics' Oncolytic Virotherapy technology uses a naturally occurring, genetically unmodified group of viruses to specifically target a wide range of cancer cells, disrupt them and stimulate an immune response against them.  Current cancer therapies – such as chemotherapies, are not specifically targeted to cancer cells and have severe side effects.  Viralytics is investigating the use of its oncolytic virotherapy products CAVATAK™ (Coxsackie A21) and EVATAK™ (ECHOvirus1) for a wide range of cancers.

ANIMATION OF CAVATAKS'™ MODE OF ACTION

POTENTIAL ADVANTAGES

The many potential, anticipated advantages of Viralytics CAVATAK™ and EVATAK™ over current chemo and radiotherapy treatments, include:

  • The potential low toxicity and greatly increased quality of life;
  • Synergies with existing Cancer Therapies  - there is clinical evidence that oncolytic virotherapy, used in combination with existing products increases the effectiveness of the treatment regime;
  • Genetically unaltered virus;
  • Mechanism of action is targeted to external receptors on cancer cells;
  • Small size (25nm) enables CAVATAK™ to disseminate more widely in the body;
  • Fast replication cycle (6 hours compared with 48 hours for some competing virotherapeutics) of CAVATAK™ and EVATAK™ leads to a greater dose generated.